# OnCo record nkt5097 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nkt5097/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nkt5097" ;
  schema:name "NKT5097"@en ;
  schema:description "NKT5097 is an experimental protein degrader from NiKang Therapeutics, in phase 1 trials for HR-positive breast cancer and CCNE1-amplified solid tumours."@en ;
  schema:url <https://onco.cc/drugs/nkt5097/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.nikangtx.com/science-and-pipeline/>, <https://clinicaltrials.gov/study/NCT07029399> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small molecule degrader, oral" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:targets <https://onco.cc/targets/cdk2/> ;
  onco:companies <https://onco.cc/companies/nikang-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07029399/> .